Pyridazine derivatives. XIX: Functionalization studies at the 5 position in the 6-phenyl-3(2H)-pyridazinone system

Journal of Heterocyclic Chemistry

Volumn 36, Issue 4, 1999, Pages 985-990

  Sotelo, Eddy ^a   Raviña, Enrique ^a   Estevez, Isabel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHENYL 3 PYRIDAZINONE; PYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONGESTIVE HEART FAILURE; DRUG SYNTHESIS; DRUG USE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

EID: 0032867660     PISSN: 0022152X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jhet.5570360426     Document Type: Article

References (20)

1. A. Montero-Lastres, R. Laguna, E. Cano, I. Estevez, and E. Ravina, Pyridazines. XVIII. 6-Aryl-3(2H)-pyridazinones inhibit influx of calcium into stimulated Platelets; Chem. Pharm. Bull., to be published.
2. D. T. Mason, Ann. Intern. Med., 80, 520 (1974).
3. S. B. Arnold, R. C. Byrd, W. Meister, K. Melmon, M. D. Cheithin, J. D. Bristow, W. W. Parmley, and K. N. Chattegee, New Engl. J. Med., 303, 1443 (1980).
4. F. J. McEvoy and G. R. Allen, J. Med. Chem., 17, 281 (1974).
5. M. Takaya, M. Sato, K. Terashima, and H. Tanazawa, J. Med. Chem., 22, 53 (1979).
6. J. A. Bristol, I. Sircar, W. H. Moos, D. B. Evans, and R. F. Weishaar, J. Med. Chem., 28, 1405 (1985).
7. E. Raviña, G. García-Mera, L. Santana, F. Orallo, and J. M. Calleja, Eur. J. Med. Chem., 20, 475 (1985).
8. N. Garcia-Domínguez, E. Raviña, L. Santana, C. Terán, G. García-Mera, F. Orallo, M. Crespo, and J. A. Fontenla, Arch. Pharm. (Weinheim), 321, 735 (1988).
9. C. Terán, E. Raviña, L. Santana, N. García, G. García-Mera, J. A. Fontenla, F. Orallo, and J. M. Calleja, Arch. Pharm. (Weinheim), 322, 331 (1989).
10. E. Raviña, C. Terán, L. Santana, N. García, and I. Estevez, Heterocycles, 31, 1967 (1990).
11. E. Raviña, C. Terán, N. G. Domínguez, C. F. Masaguer, J. Gil-Longo, F. Orallo, and J. M. Calleja, Arch. Pharm. (Weinheim), 324, 455 (1991).
12. I. Estevez, E. Raviña, and E. Sotelo, J. Heterocyclic Chem., 35, 1421 (1998).
13. R. Laguna, B. Rodríguez-Liñares, E. Cano, I. Estevez, E. Raviña, and E. Sotelo, Chem. Pharm. Bull., 45, 1151 (1997).
14. G. Cignarella, G. Grella, and M. Curzu, Synthesis, 825 (1980).
15. H. Wamhoff and F. Korte, Liebigs Ann. Chem., 724, 217 (1969).
16. The N-benzoyl(aroyl) piperazine fragment is an important pharmacophoric group present in cardiovascular agents acting compounds. Drugs as the α-adrenergic blocker Prazosin, Losulazine, Vesnarinone and others incorporate this fragment.
17. G. M. Mesfin, G. A. Johnson, M. J. Higgins, and D. F. Morris, Toxicol. Appl. Pharmacol., 87, 91 (1987).
18. Obtained by Friedel-Crafts acylation of benzene and subsequent hydrazinolysis of the resulting γ-phenyl-α, β-dibromocrotonolactone according to previously reported procedures (W. Ettel, M. Semonsky, and V. Zikan, Chem. Listy, 46, 232 (1952); (Chem. Abstr., 47, 6903) (1983).
19. Obtained by Friedel-Crafts acylation of benzene and subsequent hydrazinolysis of the resulting γ-phenyl-α, β-dibromocrotonolactone according to previously reported procedures (W. Ettel, M. Semonsky, and V. Zikan, Chem. Listy, 46, 232 (1952); (Chem. Abstr., 47, 6903) (1983).
20. P. Matyus, K. Czako, A. Behr, I. Varga, B. Poanyi, M. von Arnim, and P. Varkonyi, Heterocycles, 36, 785 (1993).